Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of KLA480 in Healthy Chinese Participants
NCT07030790Phase 1Recruiting
- Sponsor
- Kelun-Biotech
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KLA480 in Parkinson's disease (PD) (3 arms), sponsored by Kelun-Biotech. Primary endpoint: Safety and tolerability at 43 days. Started May 2025; status: recruiting.
02
Drugs
KLA480
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07030790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07030790.